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Summary Recent clinical studies have suggested that the combination of subcutaneous recombinant human
interleukin 2 (rIL-2) and interferon alpha (rIFN-m) is especially promising in advanced renal cell carcinoma.
We assessed the safety, activity and toxicity of home therapy with these two agents in 50 patients. Each
treatment cycle consisted of a 2 day pulse phase, with 9 x 106 IU m-2 of rIL-2 being given subcutaneously
every 12 h, followed by a 6 week maintenance phase during which rIL-2 1.8 x 106 IU m-2 was administered
subcutaneously every 12 h on days 1-5 and rIFN-a2b 5 x 106 IU m-2 once a day on days 1, 3 and 5.
Objective responses (CR + PR) occurred in 9/50 (18%) patients, six of whom (12%) achieved a complete
response. Disease stabilisation was observed in 17 cases (34%) and 18 patients progressed during therapy. In
the other six cases, treatment was interrupted early for toxicity or patient refusal. One patient died of
myocardial infarction during the second cycle. The overall median survival was 12 months. Home therapy with
subcutaneous rIL-2 + rIFN-a2b proved to be active, feasible and moderately toxic, but serious adverse events
can sometimes occur.
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Advanced renal cell carcinoma (RCC) has a poor prognosis,
with a mortality rate of 42-82% at 1 year (Dekernion et al.,
1978; Medeiros et al., 1988). Spontaneous regression
(generally of lung metastases) is an episodic event (incidence
rate 0.4-0.8%), usually of brief duration (Flaningan, 1987).
Moreover, advanced RCC is particularly resistant to
radiotherapy, hormonal manipulations and chemotherapy.
Because of its unpredictable natural course and the sporadic
spontaneous remission of metastases, immune response has
been supposed to play a key role in this disease and various
immunotherapeutic approaches, especially with lymphokines,
have been attempted.
Recombinant interferon alpha-2 (rIFN-a2a or b) has been
tested in several trials, leading to overall response rates of
15-20% (Quesada et al., 1985; Fossa and De Garis, 1987;
Krown, 1987). In the Division of Medical Oncology, S Carlo
Borromeo Hospital, Milan, this drug has been evaluated
alone, or in association with vinblastine, without any
appreciable difference being found in the activity of the two
treatments, thus suggesting the intrinsic activity of rIFN-a2b
(Labianca et al., 1989). Recombinant interleukin 2 (rIL-2)
appears to be a promising drug when administered int-
ravenously, as is demonstrated by the 15-20% response rate
(with some durable complete responses) reported in early
studies. However, the intravenous administration of rIL-2
implies serious toxicity, and the hospitalisation of patients
receiving the therapy must be considered mandatory.
The combination of rIL-2 plus rIFN-o2 appeared to have
synergistic activity in preclinical models, possibly related to
the efficacy of IFN in increasing the immunogenicity of
tumour cells, and therefore their susceptibility to rIL-2-
activated killer cells (Lafreniere and Rosenberg, 1985;
Cameron et al., 1988); these results made the evaluation of
rIFN-a2 and rIL-2 in clinical studies look a rational and
attractive approach.
In 1989, two clinical studies concerning the use of the
combination of intravenous rIL-2 and rIFN-o2a in the treat-
ment of various solid tumours were carried out with
encouraging results (Lee et al., 1989; Rosenberg et al., 1989).
In 1990, Atzpodien et al. (1990) reported on home treatment
of 35 patients affected with different types of advanced solid
tumours, with a combination of subcutaneous rIL-2 and
rIFN-a2b with minimal toxicity, obtaining 5/14 complete and
partial responses (CR + PR) in patients affected by advanced
RCC; this preliminary experiment was later confirmed in a
larger phase II study (Atzpodien et al., 1991).
In March 1991, we began this multicentre study with the
aim of confirming the activity and safety of this regimen.
Both referral institutions and peripheral hospitals were
involved, in order to evaluate the feasibility of the treatment
in this clinical setting.
Materials and methods
The trial involved 50 patients, aged more than 18 years, with
histologically proven metastatic or locally advanced RCC,
previously untreated or pretreated with a first-line therapy
excluding rIL-2, with good performance status (Eastern
Cooperative Oncology Group, ECOG 0-1). All of them had
measurable disease and life expectancy of at least 2 months.
An adequate bone marrow reserve [white blood count
(WBC)>4000jld-'; platelets (PLTs)> 120 000IlI; Ht>30%],
good renal function (serum creatinine< 1.5 mgml-') and the
absence of any significant liver disfunction were required;
patients with clinically significant pulmonary and cardiovas-
cular abnormalities were excluded, as were those with CNS
metastases and/or a previous history of neoplasms other than
RCC (except for basocellular carcinoma of the skin and
cervix carcinoma in situ). Prior immunotherapy, chemo-
therapy or radiotherapy had to have been discontinued at
least 4 weeks before study entry.
The patients' characteristics are listed in Table I. Thirty-
seven were men; the median age was 57 years (range: 25-77);
all had an ECOG performance status (PS) of 0-1 and 27
Correspondence: MC Locatelli, Divisione di Oncologia Medica,
Ospedale S Carlo Borromeo, Via Pio Secondo, 3, 20153 Milan, Italy
Received 9 January 1995; revised 4 July 1995; accepted 4 July 1995.IL-2 and IFN-m2b in advanced RCC
G Facendola etal
1532




Performance status (ECOG) 0/1
Prior nephrectomy (Yes/no)



























decrease in tumour size, with no simultaneous progression of
assessable disease or the appearance of new lesions; progres-
sive disease (PD) as an increase of more than 25% in
measurable lesions or the appearance of new lesions.
The sample size was calculated according to the optimal
two-stage design of Simon (1989): with the standard medical
treatments the response rate is about 15%, so, in order to
assess an increase of 20% (with a = 0.05 and P = 0.10), 19
patients were initially needed: in the case of at least four
responses, 44 patients should have been enrolled. Considering
the multicentre characteristic of this trial (with the possibility
that 10% of cases were not fully evaluable for response), an
accrual of 50 patients was planned.
Response duration and patient survival were recorded
from the initial date of treatment, with the Kaplan-Meier
method being used to plot the survival curve.
Prognostic factors were analysed by means of the chi-
square test and Yates' correction.
were asymptomatic. Nephrectomy had been performed in 36
patients (72%); locoregional disease was only present in 11
patients and the lung was the only metastatic site in 13 cases.
Forty of the patients had a diagnosis to treatment interval
(DTI) of 24 months or less. Ten patients had been previously
treated: one with radiotherapy, four with rIFN-a2b and five
with rIFN-a2b plus chemotherapy.
Drug regimen
The schedule was exactly the same as that developed by
Atzpodien et al. (1990): each treatment cycle consisted of a 2
day pulse phase with 9.0 x 106 IU m-2 of rIL-2 (Proleukin,
vials of 1.8 x 107IU - Eurocetus, Italy) being given sub-
cutaneously (s.c.) every 12 h, followed by a 6 week
maintenance phase, during which rIL-2 1.8 x 106 IU m-2 was
administered s.c. every 12 h on days 1-5 and rIFN-a2b
5.0 x 106 IU m-2 (Intron-A, vials of 3-5 x 106 IU - Schering-
Plough-Schering, USA) once a day on days 1, 3 and 5.
The patients were treated at home, with the rIL-2 and
IFN-a2b injections being self-administered at different sites.
The treatment cycles were repeated at 10 week intervals for a
total of four cycles unless the disease progressed.
Response and toxicity criteria
A clinical response evaluation was planned after the first
cycle, the WHO criteria being adopted for the evaluation of
both response and toxicity (Miller et al., 1981).
A complete response (CR) was defined as the complete
disappearance of all clinically detectable disease for a
minimum of 4 weeks; a partial response (PR) as a 50% or
greater decrease in the sum of the products of the two
longest perpendicular diameters of all measurable lesions for
at least 4 weeks, without the simultaneous progression of
assessable disease or the appearance of new lesions; stable
disease (SD) as a less than 25% increase or a less than 50%
Results
Of the 50 patients entered, six were not fully evaluable for
response because their treatment was interrupted early owing
to toxicity (see below); however, they were considered as
chemotherapy 'failures' and were included in the final evalua-
tion of response and survival.
Objective responses (CR + PR) were achieved by 9/50
patients (18%; confidence limits: 9-31%), six (12%;
confidence limits: 5-24%) being complete responders.
Disease stabilisation was observed in 17 cases (34%) and 18
patients progressed during therapy. Objective responses were
obtained after the first cycle in five patients, and after two or
three cycles in four.
Table II shows the characteristics of the responsive
patients. In the complete responders, lung was the only site
of disease in three out of six cases; one patient had a
complete response on bone metastases and is still in response
after 12 months, being off therapy for five. In no case was
the response pathologically verified and none of the patients
in partial remission was rendered 'free of disease' by means
of surgical cytoreduction.
Analysis of the responses in relation to the main prognos-
tic factors (see Table III) revealed no significant differences in
the probability of reaching an objective response, although a
trend in favour of asymptomatic patients was observed (CR,
23% vs 0 P=0.05; CR+PR, 31% vs 4% P=0.07).
The median follow-up of the population is 21 months. At
present, 6 of the 50 patients (12%) are alive and three (16%)
are still free from progression.
Figure 1 shows the overall survival curve: median survival
is 12 months. The median response duration and median
survival for objective responders were respectively 12+ and
16+ months.
Eighty courses were administered, all of them as outpatient
regimens. Toxicity was evaluable in all 50 patients, the most
frequently reported side-effects (see Table IV) being systemic
Table II Characteristics of responsive patients
Duration of
PS Prior DTI Sites of No. of Type of response Survival
Age Sex (ECOG) nephrectomy Pretreatment (months) disease courses response (months) (months)
1 58 M 0 Yes IFN >24 Local relapse 4 CR 12 32
2 54 M 0 Yes / >24 Lung 3 CR 8 12
3 70 F 0 Yes / (24 Lung 1 CR 22 22+
4 42 M 0 Yes / (24 Lung 3 CR 18+ 18+
5 61 M 0 Yes / (24 Bone 3 CR 12+ 12+
6 63 M 0 Yes / (24 Lung, adrenal 2 CR 17+ 17+
7 50 M 0 Yes / (24 Lung 4 PR 21 36+
8 73 M 0 No / <24 Pleura 3 PR 8 21+
9 59 M 1 Yes IFN >24 Lung, bone 4 PR 10 27
PS, performance status; DTI, diagnosis to treatment interval.symptoms, such as fever, fatigue, anorexia, myalgia and
arthralgia; weight-loss of more than 5% of initial weight was
observed in only four (8%) patients. Some patients showed
erythema and subcutaneous infiltration at the sites of the
rIL-2 injections, but this was never a reason for interrupting
treatment. There was no case of fluid retention, leucopenia
was never observed and no patient had any concurrent infec-
tion.
Two patients refused further therapy after 2 and 4 weeks
of the first cycle because of prolonged and intense fatigue. In
four cases, the administration of rIL-2 + rIFN-a2b was stop-
ped because serious toxicity developed after 2-4 weeks of
IL-2 and IFN-a2b in advanced ROC
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treatment: one case of allergy (generalised erythematopapular
rash), one of reversible thrombocytopenia (grade 4), one of
grade 4 hepatic toxicity and one of acute pancreatitis pos-
sibly related to treatment. In all of these cases, the toxicity
completely resolved within 1 month of the discontinuation of
treatment.
Furthermore, a 66-year-old male patient treated for a ret-
roperitoneal lymph node recurrence, who had had no
previous cardiovascular disease and showed no signs of any
concomitant risk factor, developed a lethal acute myocardial
infarction during the 5th week of the second cycle while he
was in stable disease.
Table III Objective responses in relation to main prognostic factors
Prognosticfactor CR (%) CR + PR (%)
PS 0 6/26 (23) 8/26 (31)
P= 0.07 P= 0.09
1 0 1/24 (4)
No. of sites ofdisease 1 5/22 (23) 6/22 (28)
P=0.165 P=0.37
>1 1/28 (3.5) 3/28 (11)
Sites ofdisease Only lung 3/13 (23) 4/13 (30.7)
P = 0.385 P = 0.39
Others 3/37 (8.1) 5/37 (13.5)
DTI >24 2/10 (20) 3/10 (30)
P=0.8 P=0.66
<24 4/40 (10) 6/40 (15)











Table IV Toxicity (WHO criteria)
Grade I Grade 2 Grade 3 Grade 4
Fever 5 22 10 8
Fatigue and/or anorexia 20 10 15 0
Myalgia/arthralgia 5 1 0 0
Rash 3 4 0 0
Nausea/vomiting 6 2 0 0
Diarrhoea 0 0 0 0
Leucopenia 4 1 1 0
Thrombocytopenia 0 0 0 1
Hepatic toxicity 3 4 1 1
Pancreatitis 0 0 0 1
Hypotension 2 3 0 0
Cardiotoxicity 0 0 0 1
Allergy 0 0 1 0
Table V Subcutaneous IL-2 and IFN regimens for metastatic renal cell carcinoma
No. of
Reference rIL-2 IFN-c patients OR (%) CR (%)
Atzpodien et al. (1991) 1.44-1.8 x 107 IU m-2 on days 1 and 2 5.0 x 106 IU m-2 on days 1, 3 and 5 for 34 10 (29) 11.76
3.6-4.8 x 106 IU m-2 on days 1-5 6 weeks
for 6 weeks
Ratain et al. (1993) 0.5-2.5 x 106 IU m-2 on days 1-5 for 0.25-1.25 x 107 IUm-2 on days 1, 3 16 4 (25) 0.00
4 weeks, every 1-3 weeks and 5 for 4 weeks, every 1-3 weeks
Vogelzang et al. (1993) 4 x 106 IU m-2 on days 1-4 for 4 weeks 9.0 x 106 IU m-2 on days 1-4 for 42 5 (12) 4.76
4 weeks
Negrier et al. (1993) 1.44-1.8 x 107 IUm-2 on days 1 and 2 5.0 x 106 IUm-2 on days 1, 3 and 5 for 24 NR (12) NR
3.6-4.8 x 106 IU m-2 on days 1-5 for 6 weeks
6 weeks
Present data 1.8 x 107 IU m-2 on days 1 and 2 5.0 x 106 IU m-2 on days 1, 3 and 5 for 50 9 (18) 12.00
3.6 x 106 IU m-2 on days 1-5 for 6 weeks
6 weeks
Atzpodien et al. (1995) 2.0 x 107 IU m-2 on days 3-5, weeks 1 6.0 x 106 IU m-2 on day 1, weeks 1 152 38 (25) 6.00
and 4 and 4; days 1, 3 and 5, weeks 2, 3, 5
5 x 106IU m-2 on days 1, 3 and 5, and 6
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Discussion
Advanced RCC is still one of the challenges of the nineties:
although new therapeutic approaches seem to have increased
the rate of objective responses (with some lasting complete
responses), too many patients have a natural history that
seems to be independent of the medical treatment they
receive.
Since Rosenberg's (1988) first report of the impressive
results obtained using intravenous rIL-2 with or without
lymphokine-activated killer (LAK) cells, a number of other
experiences with lymphokine in bolus or as a continuous i.v.
infusion were described as having achieved objective res-
ponses of 0-40%.
Further phase I-I1 studies using an association of int-
ravenous rIL-2 and rIFN-m2b were subsequently carried out,
with a cumulative response rate of 21% (Ratain et al., 1992).
In 1991 Atzpodien et al. published a report concerning a
phase II clinical trial using a combination of the two lym-
phokines, but with rIL-2 being administered subcutaneously
in order to avoid the severe toxicity associated with its
intravenous administration and to make it possible to treat
patients in an outpatient setting. An objective response of
29% was observed in the 34 patients who self-administered
the treatment at home; the courses were well tolerated and
did not give rise to any major side-effects.
Table V summarises the results of the trials so far carried
out using the combination of subcutaneous rIL-2 and rIFN-
a2b. After a phase I study carried out in several solid
tumours (Ratain, 1992), the University of Chicago conducted
a phase II co-operative trial in subjects affected only by
advanced RCC (Vogelzang et al., 1993).
The encouraging results suggested by the earlier phase I
trial were not fully confirmed by this later study, at least not
in terms of the response rate, although median survival was
good and only mild toxicity was observed. In this trial, the
chosen dose intensity was less than that used in Atzpodien's
first trial and no induction therapy was administered, but we
cannot state if this dose modification was the reason for the
lower response rate. In fact, even if a direct dose-response
correlation with rIL-2 administration has been found in ex-
perimental models, the recently published North American
trial (Yang et al., 1994) comparing high-dose intravenous
rIL-2 vs a low-dose intravenous regimen in advanced RCC
does not demonstrate a significant difference in the incidence
of objective responses (20% vs 15%).
Nevertheless, Negrier et al. (1993), who used the same
regimen of subcutaneous rIL-2 as that of Atzpodien, have
reported only a 12% response rate in 24 patients.
A recent report of a German multi-institutional trial in 152
patients with subcutaneous rIL-2 plus IFN-a administered at
higher doses than that used in the earlier study confirms the
good results of subcutaneous home-therapy (25% of overall
response rate) with an acceptable toxicity (Atzpodien et al.,
1995).
Given that the present phase II multicentric study was the
first and largest experiment performed with the aim of
confirming Atzpodien's data, the same low-dose regimen was
used and, in an adequate number of patients (50), our data
show a similar response rate.
The incidence of response was higher in asymptomatic
patients (a well-known prognostic factor in this neoplasia),
but this difference did not reach statistical significance, prob-
ably because of the limited size of the population. In such a
resistant tumour, these results can be considered encourag-
ing. The general compliance of patients to the treatment was
good, with only two patients refusing treatment for subjective
symptoms; no case of serious side-effects related to the capil-
lary leak syndrome was observed, and the grade 4 toxicities
were sporadic and reversible.
The expected cardiac toxicity (hypotension and/or arryth-
mia) was not observed in our series of patients; nevertheless
it cannot be ruled out that the one case of myocardial
infarction was not related to rIL-2 administration. This un-
predictable potential toxicity of rIL-2, although very rare,
strengthens the importance of carefully selecting subjects to
submit to this treatment, even when using this more
manageable and tolerable route of administration and at this
dose. In this respect, the multivariate analysis of prognostic
factors, and the consequent definition of some risk categories
of patients affected with advanced RCC, as suggested by
Palmer et al. (1992), might provide additional help in
deciding when and whom to treat with this biological
therapy.
In conclusion, the objective response rate obtained in the
present study shows that subcutaneous rIL-2 + rIFN-a2b is a
good therapeutic option for oncologists treating advanced
RCC; this is confirmed by an analysis of retrospective data
relating to advanced RCC patients treated with intravenous
or subcutaneous rIL-2, which supports the fact that both
routes of administration lead to a similar response rate but
that the toxicity profile favours the subcutaneous route
(Palmer et al., 1993).
Nevertheless, other aspects of treatment with rIL-2 deserve
further evaluation, such as its optimal dose and its associa-
tion with IFN and other chemotherapeutic agents; to this
end we are currently conducting a phase II randomised study
of subcutaneous rIL-2 with or without rIFN-a2b.
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